x

Posted 27 April, 2022

Cell MedX Corp. appointed new CEO

CEO Change detected for ticker OTC:CMXC in a 8-K filed on 27 April, 2022.


  In addition, Mr. Yaretz was appointed Chief Executive Officer of the Company, replacing Mr. McEnulty, who resigned from his position as CEO of the Company on April 25, 2022.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Cell MedX Corp.
Health Care/Life Sciences • Pharmaceuticals
Cell MedX Corp. is a biotech company, which engages in the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness. Its products include microcurrent therapy and eBalance systems. The company was founded on March 19, 2010 and is headquartered in Carson City, NV.
Market Cap
$8.84M
View Company Details
Cell MedX Corp. by TradingView
Relevant filing section
ITEM 5.02
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS 


On April 25, 2022, the board of directors of Cell MedX Corp. (the "Company") unanimously resolved to increase the number of directors of the Company to six directors and to appoint Mr. Dwayne Yaretz as a director to fill the vacancy created by the increase in the number of directors. In addition, Mr. Yaretz was appointed Chief Executive Officer of the Company, replacing Mr. McEnulty, who resigned from his position as CEO of the Company on April 25, 2022. Mr. McEnulty will continue to serve on the Company's board of directors.


Mr. Yaretz' experience spans many industries including the development of industrial and medical imaging devices. He has aided in the re-structure of numerous companies by identifying and recruiting key personnel, enhancing the management team, capitalization, and maximizing business and sales opportunities. In the past, Mr. Yaretz has acted as a director, and held various top management positions, including CEO, CFO and president, with both private and public companies.


There is no family relationship among the directors. There are currently no compensation arrangements with Mr. Yaretz for acting as a member of the board of directors, or as the CEO.


A copy of the Company's news release regarding the appointment of Mr. Yaretz and resignation of Mr. McEnulty is attached as Exhibit 99.1 hereto.